Differentiating therapy in acute myeloid leukemia

Leukemia

Volumn 10, Issue SUPPL. 2, 1996, Pages

  Tallman, M S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AML; APL; ATRA

Indexed keywords

RETINOIC ACID;

ACUTE DISEASE; CELL DIFFERENTIATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE TRANSLOCATION; GENETICS; HUMAN; MYELOID LEUKEMIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE DISEASE; CELL DIFFERENTIATION; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE II; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; RANDOMIZED CONTROLLED TRIALS; TRANSLOCATION, GENETIC; TRETINOIN;

EID: 4243266642     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Sachs L. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature 1987; 274: 535-538.
2. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci 1980; 77: 2936-2940.